In 1993, The U.S. Food and Drug Administration (FDA) added new CBER reviewers to streamline biologics review. User fees were enacted.

The proportion of adverse-event reports classified as serious increased between 1992 and 1994, and the quality of event reporting to FDA improved since the introduction of MedWatch.